Drug Trial Radar · NCT00823628
Contrast-medium Induced Nephrotoxicity in Patients Undergoing Coronary Angiography - Iodixanol Versus Iopromide
Last checked: Nov 19, 2026Latest source record: Jul 7, 2010 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
420
Planned (sponsor's estimate)
Start
Feb 2009
Primary completion
May 2010
Study completion Jun 2010
Sponsor
- Lead sponsor
- Seoul National University Bundang HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jan 15, 2009
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
In the treatment of coronary heart disease which is the major cause of heart attack, direct mechanical treatment with catheters such as the coronary angiography, coronary balloon intervention and stenting intervention are the mainstay of therapy in recent years. In that procedures, the investigators should use the contrast media, and it may cause kidney toxicity especially in the patients with underlying kidney disease and decreased kidney function. The investigators intended to find out which contrast agent has less kidney toxicity in the catheter based treatment of coronary arterial diseases in patients with underlying decreased kidney function
Conditions
- Chronic Renal Insufficiency
- Coronary Angiography
Interventions
contrast agent (iopromide)Drug
coronary angiography using the allocated contrast agent
contrast agent (iodixanol)Drug
coronary angiography using the allocated contrast agent
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of contrast induced nephropathy, defined as either a relative increase in serum creatinine from baseline of >=25% or an absolute increase of >=0.5mg/dL(44.2µmol/L)Time frame: days 1 and 2
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Cardiovascular Center, Seoul National University Bundang Hospital
Seongnam-si, Gyeonggi-do, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.